---
title: Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
nct_id: NCT02585843
overall_status: COMPLETED
phase: PHASE2, PHASE3
sponsor: Columbia University
study_type: INTERVENTIONAL
primary_condition: Heart Failure
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02585843.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02585843"
ct_last_update_post_date: 2019-08-08
last_seen_at: "2026-05-12T06:46:58.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

**Official Title:** Pilot Study of Natriuretic Versus Standard Doses of Mineralocorticoid Receptor Antagonists in Heart Failure and Loop Diuretic Resistance in Outpatients

**NCT ID:** [NCT02585843](https://clinicaltrials.gov/study/NCT02585843)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Columbia University
- **Conditions:** Heart Failure
- **Start Date:** 2015-11
- **Completion Date:** 2017-03-31
- **CT.gov Last Update:** 2019-08-08

## Brief Summary

This is a prospective, single-center, double-blind and randomized placebo controlled trial for evaluation of a 7-day 100mg daily dose of spironolactone on weight loss and resolution of signs and symptoms of congestion in outpatients with acute decompensated heart failure (ADHF). Patients who are not responding to their current loop diuretics will be considered for this study. Mineralocorticoid receptor antagonists (MRAs) are recommended as standard of care in management of heart failure (HF) patients. However, recommended doses of MRAs (spironolactone 25mg/daily or eplerenone 50mg/daily) will not have any impact on signs and symptoms of volume overload. Therefore, the proposed study will aim to show the impact of this outpatient regimen to improve diuresis and possible reduction in hospitalization for further diuretic management in HF patients with signs and symptoms of congestion.

## Detailed Description

The incidence and prevalence of heart failure (HF) is rising with more than 5 million Americans suffering from this syndrome. Hospitalization rates for acute decompensated heart failure (ADHF) are also remarkably high, exceeding more than 1 million admissions per year. Congestion is the main cause of hospitalization for ADHF. Loop diuretics as the main therapy for decongestion, often are not adequate since many patients with ADHF develop "loop diuretic resistance". These patients will require hospitalization for intravenous diuretic or other advanced decongestion therapies. Thus, novel decongestion therapies are needed to decrease hospital admission rates and subsequent complications of multiple hospitalizations. Hyperaldosteronism, not only is a pivotal pathogenic factor in HF, but also contributes to loop diuretic resistance. Attempts for normalization of circulatory aldosterone with mineralocorticoid receptor antagonists (MRAs), mainly spironolactone, have shown to decrease mortality in HF patients with reduced left ventricular ejection fraction (LVEF). Moreover, MRAs significantly decrease the rate of rehospitalization in both HF with preserved and reduced LVEF. The dose of spironolactone in these trials is 25mg daily. However, this dose does not increase natriuresis (urinary sodium excretion). Natriuresis is achieved with higher doses of MRAs. Therefore, the primary aim of this study is to examine the efficacy of 7-day 100mg daily of spironolactone on weight loss and resolution of signs and symptoms of congestion in patients aged 60 years with ADHF and loop diuretic resistance.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* History of heart failure with either reduced or preserved ejection fraction for 3 months
* Patients with New York Heart Association (NYHA) class II- IV heart failure symptoms, with at least one worsening symptom (Dyspnea on exertion, shortness of breath, orthopnea, early satiety) and one sign of congestion (pulmonary rales, elevated jugular venous pressure10cmHg, peripheral edema and ascites)
* Decision by primary cardiologist or heart failure (HF) specialist to increase the home diuretic dose
* Stable treatment with beta-blockers for 1 month unless contraindicated (i.e. intolerance, bradycardia) as specified by primary cardiologist/HF provider
* Stable treatment with angiotensin converting enzyme-1 (ACE-1) or angiotensin receptor blocker (ARB) for 1 month
* Spironolactone dose 25mg or eplerenone 50mg per day
* Daily furosemide or furosemide equivalent dose of 80mg or greater
* Serum potassium concentration 4.5 mmol/L or 5.0 mmol/L if on potassium supplements
* Estimated Glomerular Filtration Rate (eGFR) by Modification of Diet in Renal Disease (MDRD) equation 40 ml/min/1.73

Exclusion Criteria:

* Inability to complete informed consent form
* Allergy or intolerance to spironolactone
* Systolic blood pressure \<100 mmHg
* Patient in need of hospitalization per cardiologist decision
* Current inotrope dependency
* Current mechanical circulatory support
* Acute coronary syndromes or unstable angina within the past 4 weeks
* History of cardiac transplant
* Obstructive cardiac valvular disease
* Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy
* Significant ventricular arrhythmia necessitating defibrillator therapy within the past 14 days
* Atrioventricular conduction abnormality greater than first-degree block
* Primary liver disease resulted in cirrhosis or abnormal liver function tests (transaminases and alkaline phosphatase levels 3 times the upper limit of normal
* Acute malignancy
* Active infection requiring antimicrobial treatment (Suppression antimicrobial for chronic infections are exempt)
```

## Arms

- **High-dose** (EXPERIMENTAL) — Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
- **Standard of Care** (ACTIVE_COMPARATOR) — Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)

## Interventions

- **Spironolactone 100mg** (DRUG) — 2 capsules of study medication consist of 100mg, PO (oral) for 7 days
- **Spironolactone 25mg** (DRUG) — 25mg/day of spironolactone

## Primary Outcomes

- **Change in Body Weight** _(time frame: 7 days)_ — change in body weight measured in kilograms between weight at baseline and weight at 7 days

## Secondary Outcomes

- **Change in Estimated Jugular Venous Pressure (cmH2O)** _(time frame: 7 days)_
- **Change in 6-minute Walk Test Distance (6MWT)** _(time frame: 7 days)_
- **Change in Score on the Visual Analogue Scale (VAS)** _(time frame: 7 days)_
- **Change From Baseline to Day 7 on the Seven-Level Likert Scale** _(time frame: 7 days)_

## Locations (1)

- Columbia University Medical Center, New York, New York, United States

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.columbia university medical center|new york|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02585843.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02585843*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*